Suven Gets Product Patents in Australia, Eurasia and Europe | CORPORATE ETHOS

Suven Gets Product Patents in Australia, Eurasia and Europe

By: | May 9, 2018

May 8: Hyderabad-based biopharma major Suven Life Sciences Ltd (Suven) on Wednesday announced the grant of one product patent each from Australia (2014404001), Eurasia (029365) and Europe (3099675) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

According to the company, the granted claims of the patents include the class of selective 5-HT4 compound and is being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven shares were trading at Rs 186, up 0.84% from the previous closing of Rs 184.45, on BSE at 11.03 am today.